NASDAQ OMX

GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China

Dela

BEIJING and HONG KONG, June 22, 2018 (GLOBE NEWSWIRE) -- On June 22, the Graduate Management Admission Council (GMAC) joins hands with 11 leading business schools in China to launch the "Study in China" initiative. This partnership marks the opening of an interactive platform for international students across 20 Belt and Road (B&R) regions to explore opportunities in China and to pursue higher education in business-related fields. The "Study in China" initiative aims to meet rapidly growing international student demand and to champion China as a world-class study destination and emerging global hub for business education.

The "Study in China" online portal (www.studyinchinamba.com) officially launched today allows students to discover more about studying and living in China. The newly designed English-language website connects prospective students with partner business schools and offers access to an abundance of information to help find the perfect fit for their China education experience. GMAC's gateway guides international applicants from these Belt and Road regions in Asia, the Middle East, Africa, and Europe through the necessary steps to begin a new learning chapter in one of the most dynamic economies in the world. It offers in-depth information and insider advice on the schools and programs available, including international program structure, syllabus overview, admission requirements, application times, campus facilities, scholarships and financial aid. Students can also opt-in to conveniently contact the schools for further detail via GMAC's one-stop portal.

To offer a glimpse into the great opportunities available, GMAC is organizing a "Study in China" contest from June 22 to August 31. Participants submit short essays about why they want to study in China to win a round-trip to China. Three selected winners will be awarded return economy flights and campus accommodation to visit preferred business schools and enjoy a first-hand experience of the school and campus life.

The new initiative partners with China's most prestigious business schools located in Beijing, Shanghai, and Hong Kong. The top-ranked institutions include Antai College of Economics and Management, Shanghai Jiao Tong University; China Europe International Business School; CUHK Business School, The Chinese University of Hong Kong; School of Management, Fudan University; HKUST Business School, The Hong Kong University of Science and Technology; Guanghua School of Management, Peking University; Business School, Renmin University of China; School of Economics and Management, Tsinghua University; BiMBA Business School of the National School of Development, Peking University; Cheung Kong Graduate School of Business; and HKBU School of Business, Hong Kong Baptist University.

Mr. Sangeet Chowfla, the President and CEO of GMAC, announced GMAC's pride in creating more opportunities for prospective students to access business education. He believes "This will effectively connect international talent with the right opportunities to excel at China's leading business schools and programs, while offering students all around support during the study abroad period." Mr. Chowfla emphasized GMAC's observations over the past few years, as China holds the potential "to become one of the most popular study destinations." This "Study in China" initiative, according to Chowfla, intends to further raise the profile of business schools in China and showcase the value of business education to international candidates.

Professor Lu Xiongwen, Dean of the School of Management at Fudan University, expressed his congratulations on the launch of the new initiative and extended a warm welcome to prospective students looking to come study in China. He quoted an old Chinese proverb that says, "Practice goes deeper than theoretic knowledge," indicating that these programs would open new doors of understanding. "I believe this learning journey will present you a broad picture of China's economic trends at present and future, the uniqueness of Chinese business models as well as different features of the Chinese market and global market," said Prof. Lu. "You will also enjoy the opportunity of learning about and appreciating China's profound culture immersed in thousands of years of history."

Professor Kar Yan Tam, Dean of the HKUST Business School, also commented on the initiative, saying that "China will remain the world's major growth engine in the years ahead, with reforms to allow its economy to unleash new potential and the Belt and Road initiative to bring a sustained momentum to the region." He also highlighted that "Students should not only receive the best international business education to develop a global perspective, but also look for opportunities to experience the vitality of China. Hong Kong is a dynamic and international city where students can enjoy access to a unique fusion of East and West. The city also stays at the forefront of business education and offers different enriching and diverse learning experiences to prepare students for a flourishing career in China and beyond."

The "Study in China" initiative exemplifies GMAC's consistent efforts in promoting business education around the world. This network acts as a bridge within the B&R community to empower students' professional journeys as future business leaders and entrepreneurs in China and abroad.

About GMAC:  The Graduate Management Admission Council (GMAC) is a global, non-profit association of leading graduate business schools. Founded in 1953, we are committed to creating solutions for business schools and candidates to better discover, evaluate and connect with each other. We work on behalf of the schools and the graduate management education community, as well as guide candidates on their journey to higher education, to ensure that no talent goes undiscovered.

GMAC provides world-class research, professional development opportunities and assessments for the industry, designed to advance the art and science of admissions. Owned and administered by GMAC, the Graduate Management Admission Test® (GMAT®) is the most widely used graduate business school assessment, recognized by more than 7,000 programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive programs around the world. Our flagship portal for graduate management education resources and information, www.mba.com, receives 14 million visits a year and features the School Search matching tool and Graduate Management Admission Search Service (GMASS), matching candidates and business schools.  

GMAC is based in the United States with offices in the United Kingdom, India, and Hong Kong. To learn more about our work, please visit www.gmac.com.

Media contact: 
Yolanda Kwok, Regional Director, Greater China, GMAC
ykwok@gmac.com

Susanna Lee, Associate Director, Marketing, Greater China, GMAC
slee@gmac.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum